BPC-157: Discovery and Regulatory History How BPC-157 traveled from a 1993 gastric-cytoprotection hypothesis at the University of Zagreb, through Pliva's PL14736 clinical program, to research-use-only status and a 2022 WADA Monitoring Program listing
Notably, LLC has been proven to be a highly aggressive and poorly immunogenic tumor model, unresponsive to mono- and bi-modal therapies, such as radiotherapy and immune checkpoint blockade [78]
Tests involving multiple factors were analyzed using either a three-way analysis of variance (ANOVA) with diet, time, and sex as variables, a two-way ANOVA with diet and time as variables, followed by Sidaks post hoc test, a two-way repeated measures (RM) ANOVA for longitudinal data, followed by Dunnetts post hoc test or by one-way ANOVA followed by Tukeys post hoc test as specified in the figure legends
10.1038/s41583-022-00558-9 101 De FilippisF.PellegriniN.VanniniL.JefferyI
10.1016/j.freeradbiomed.2024.04.229 43 DegterevA.HitomiJ.GermscheidM.ChenI
